Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATG Fresenius observational study on the prevention of GvHD in allogeneic stem cell transplant patients - ATOS

Trial Profile

ATG Fresenius observational study on the prevention of GvHD in allogeneic stem cell transplant patients - ATOS

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2019

At a glance

  • Drugs Ciclosporin; Methotrexate
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms ATOS
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 14 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top